SPECT images using99mTc(V)-DMS in lung metastasis of osteosarcoma

Ohta, Hitoya; Tsuji, T.; Endo, Keigo; Fujita, T; Konishi, Junji; Kotoura, Yoshihiko; Yamamuro, Takao

doi:10.1007/bf03164564

Cited by 13 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tc-99m (V) DMSA has been reported to accumulate in primary LC [14,15] and its bone metastases. Ohta et al [16] have reported a case where Tc-99m (V) DMSA uptake was displayed in lung metastases from osteosarcoma. In our study group, Tc-99m (V) DMSA scans successfully showed all PTs in all but one of the LC patients (patient no.…”

Section: Discussionmentioning

confidence: 97%

The role of Tc-99m (V) DMSA scintigraphy in the diagnosis and follow-up of lung cancer lesions

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 97%

The role of Tc-99m (V) DMSA scintigraphy in the diagnosis and follow-up of lung cancer lesions

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Furthermore, RGS was able to localize more tumor‐involved lesions (> 30%) in patients with recurrent MTC compared with conventional preoperative imaging modalities and surgical findings. It is important to note that 99m Tc(V)‐DMSA uptake also has been confirmed in patients with soft tissue sarcoma, osteosarcoma, prostatic carcinoma, benign and malignant head and neck tumors, and inflammatory lesions 31–33…”

Section: Discussionmentioning

confidence: 98%

Radioisotope-guided surgery in patients with pheochromocytoma and recurrent medullary thyroid carcinoma

Adams

Lorenz

et al. 2001

Cancer

View full text Add to dashboard Cite

BACKGROUND The objective of this study was to appraise the detection of metastases of medullary thyroid carcinoma (MTC) and pheochromocytoma using radioguided surgery (RGS) and to compare the results with external imaging modalities, surgical palpation, and histopathologic findings. METHODS Twenty‐five patients with recurrent MTC underwent preoperative scintigraphic imaging with 500 megabecquerels (MBq) of technetium 99m(V)‐dimercaptosuccinic acid [99mTc(V)‐DMSA] and 222 MBq of indium 111 (111In)‐pentetreotide. The radiopharmaceutical that showed the greatest preoperative tumor uptake was selected for intraoperative RGS. Surgery was performed 24 hours after the administration of 111In‐pentetreotide or 4 hours after the injection of 99mTc(V)‐DMSA. Furthermore, three male patients underwent surgery who suffered from recurrent pheochromocytoma (injection of 180 MBq iodine 123‐labeled metaiodobenzylguanidine [123I‐MIBG] 4–5 hours before surgery). RESULTS Overall, lesion detection sensitivities in patients with MTC for computed tomography, 111In‐pentetreotide, and 99mTc(V)‐DMSA were 32%, 34%, and 65%, respectively. Surgical palpation identified lymph node metastases of recurrent MTC with a sensitivity of 65%, whereas RGS localized 64 malignant lesions (sensitivity, 97%). Altogether, 71 lesions could be excised, 5 of which were adjudged false positive with respect to MTC metastases. Both surgical palpation and RGS localized all paravertebral subdiaphragmatic lesions (size ≥ 2 cm) of recurrent pheochromocytoma seen in the preoperative MIBG scan. CONCLUSIONS RGS was capable of localizing more and smaller metastases of MTC compared with conventional imaging modalities and surgical palpation. However, the relatively high radioligand accumulation in the kidneys (111In‐pentetreotide) and the dense hepatic and biliary signals using MIBG limited their use for intraoperative detection of tumors in the area of the adrenal gland. Cancer 2001;92:263–70. © 2001 American Cancer Society.

show abstract

“…99m Tc(V)-DMSA has been extensively studied as a tumor-imaging agent and is being used in imaging medullary thyroid carcinoma, [1][2][3] head and neck tumors 4,5 and metastases from breast carcinoma in liver, brain and skeleton. [6][7][8] Re(V)-DMSA for clinical studies is performed using stannous chloride as the reducing agent.…”

Section: Introductionmentioning

confidence: 99%

Kidney uptake of ^186/188Re(V)‐DMSA is significantly reduced when the reducing agent is changed from stannous ion to metabisulfite

Kothari

Satpati

Mukherjee

et al. 2002

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

We describe the work carried out on the preparation of 186/188Re(V)‐DMSA, which showed lower kidney retention, formulated by using metabisulfite as the reducing agent. The complex was prepared by reducing 186/188ReO4− (100 μg, 0.54 μM, ∼150 MBq) in the presence of Na2S2O5 (30 mg, 0.15 mM) and reacting with DMSA (10 mg, 0.05 mM) in saline at pH 3.5 and at 80°C for 1 h. The complex was characterized by TLC using acetone and saline as two different solvent systems. Reverse phase HPLC carried out using isocratic system with 90:10 water/acetonitrile mobile phase showed the existence of four species. Biodistribution studies were carried out in albino mice with 186/188Re(V)‐DMSA prepared via metabisulfite reductant [186/188Re(V)‐DMSA (MBS)] as well as stannous chloride reductant [186/188Re(V)‐DMSA (SnCl2)]. The distribution patterns were similar except for kidney uptake. Kidney retention in case of 186/188Re(V)‐DMSA (MBS) was lower [0.68 (±0.06)%/g] than that observed in case of 186/188Re(V)‐DMSA (SnCl2) [2.93(±0.93)%/g] after 24 h p.i. Though bone uptake was initially similar with both the preparations, there was substantial decrease in bone activity after 24 h p.i. with 186/188Re(V)‐DMSA (MBS). In vitro cell uptake studies were carried out with 186/188Re(V)‐DMSA (MBS), 186/188Re(V)‐DMSA (SnCl2) and 99mTc(V)‐DMSA using Ehrlich Ascites Tumor Cell Lines. Approximately 15% cell uptake was observed with 186/188Re(V)‐DMSA (MBS) as well as with 186/188Re(V)‐DMSA (SnCl2) and was comparable with that of 99mTc(V)‐DMSA (19%). Our studies indicate that 186/188Re(V)‐DMSA prepared by using metabisulfite as a reducing agent has potential for use in targeted radiotherapy of medullary thyroid carcinoma. Copyright © 2002 John Wiley & Sons, Ltd.

show abstract

SPECT images using99mTc(V)-DMS in lung metastasis of osteosarcoma

Cited by 13 publications

References 3 publications

The role of Tc-99m (V) DMSA scintigraphy in the diagnosis and follow-up of lung cancer lesions

The role of Tc-99m (V) DMSA scintigraphy in the diagnosis and follow-up of lung cancer lesions

Radioisotope-guided surgery in patients with pheochromocytoma and recurrent medullary thyroid carcinoma

Kidney uptake of ^186/188Re(V)‐DMSA is significantly reduced when the reducing agent is changed from stannous ion to metabisulfite

Contact Info

Product

Resources

About

SPECT images using99mTc(V)-DMS in lung metastasis of osteosarcoma

Cited by 13 publications

References 3 publications

The role of Tc-99m (V) DMSA scintigraphy in the diagnosis and follow-up of lung cancer lesions

The role of Tc-99m (V) DMSA scintigraphy in the diagnosis and follow-up of lung cancer lesions

Radioisotope-guided surgery in patients with pheochromocytoma and recurrent medullary thyroid carcinoma

Kidney uptake of 186/188Re(V)‐DMSA is significantly reduced when the reducing agent is changed from stannous ion to metabisulfite

Contact Info

Product

Resources

About

Kidney uptake of ^186/188Re(V)‐DMSA is significantly reduced when the reducing agent is changed from stannous ion to metabisulfite